A collaborative research effort between the University of Michigan and the University of California San Diego has identified a critical…
Read More

A collaborative research effort between the University of Michigan and the University of California San Diego has identified a critical…
Read More
The U.S. Food and Drug Administration (FDA) has recently issued a significant approval for AbbVie’s antibody-drug conjugate (ADC) targeting blastic…
Read More
The Challenge of Estrogen Receptor-Positive Breast Cancer Estrogen receptor-positive (ER+) breast cancer represents approximately 70% to 80% of all breast…
Read More
The US Food and Drug Administration (FDA) has granted a pivotal approval for Datroway (datopotamab deruxtecan), a novel antibody-drug conjugate…
Read More
The Hidden Threat of Estrogen Receptor-Positive Breast Cancer Estrogen receptor-positive (ER+) breast cancer is the most prevalent form of the…
Read More
In a breakthrough study published in the Journal of Clinical Investigation, researchers from the University of Michigan and the University…
Read More
Researchers from the University of Michigan and the University of California San Diego have published a groundbreaking study identifying the…
Read More
This fundamental discovery, detailed in a collaborative study by researchers from the University of Michigan and the University of California…
Read More
The study, published in the Journal of Clinical Investigation, identifies a sophisticated "smuggling" operation between cancer cells and the bone…
Read More
The persistence of estrogen receptor-positive (ER+) breast cancer remains one of the most formidable challenges in modern oncology, as patients…
Read More